New York, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Packaging Products and Services Market by Type of Therapy, Package Engineering Design, Scale of Operation and Geography : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06130493/?utm_source=GNW Presently, more than 30 cell-based therapy products have received marketing approvals across various geographies, while more than 1,000 therapeutic candidates are under clinical evaluation. Considering the lucrative investment opportunity within this domain, several investors are actively supporting ongoing / future product development programs in this upcoming field of pharmacological interventions. In fact, there has been a 240% increase in investment activity, in terms of capital amount invested, between 2019 and 2020. However, the ultimate success of cell therapies is dependent on the safe and timely delivery of viable doses of therapeutic cells to the right patient. In this context, it is worth highlighting that drug product manufacturing, packaging and logistics operations involving cell therapies are both complex and challenging. Moreover, in order to ensure the stability of such products across the supply chain, specific temperature conditions (cryogenic, ambient or refrigerated) are required, in addition to specialized packaging material. Considering that most cell therapies are personalized, it is imperative that errors in labeling are avoided at all costs.
Given the need for costly and specialized equipment and the complexities associated with handling cell-based therapy products, innovators in the healthcare industry are likely to involve contract service providers for their drug product production, packaging and transportation requirements. Over time, regulators across the world, including the US Food and Drug Administration (FDA) and the International Air Transport Association (IATA), have established guidelines for the packaging, storage and transport of cell therapies. Since CMOs / CDMOs with the necessary capabilities to handle cell therapies are also likely to have established processes that comply with the current acceptable standards across different global regions, it is better for therapy developers to strategically partner with the aforementioned players instead of focusing on developing in-house capabilities. Presently, close to 60 companies claim to be offering cell therapy packaging services and associated products. In fact, it is estimated that close to 30% of drug substance and drug product related operations of advanced therapy medicinal products are already outsourced to capable CMOs / CDMOs. Further, over the last few years, several service providers have also forged strategic alliances among themselves, in order to further expand existing capabilities and augment their respective service offerings. Given the rising trend of outsourcing in the healthcare industry, and the ongoing efforts of service providers to further improve their portfolios, we believe that the cell therapy packaging products and services market is likely to evolve at a steady pace in the next few years.
SCOPE OF THE REPORT The Cell Therapy Packaging Products and Services Market by Type of Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies and Other ATMPs), Package Engineering Design (Primary and Secondary Packaging), Scale of Operation (Clinical and Commercial) and Geography (North America, Europe, Asia Pacific and Rest of the World) , 2021-2030 report features an elaborate study of the current scenario and future opportunity within the cell therapy packaging products and services market. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes: An overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis based on their year of establishment, company size, location of headquarters, package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen), type of passive system used, temperature ranges supported, type of cells handled and additional services offered. A detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players. An in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies). An analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership. A list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate). A case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies. Detailed profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.
One of the key objectives of the report was to estimate the existing market size and future growth potential of the cell therapy packaging providers market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented across [A] type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), [B] package engineering design (primary and secondary packaging), [C] scale of operation (clinical and commercial) and [D] geography (North America, Europe, Asia Pacific and Rest of the World)
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
KEY QUESTIONS ANSWERED Who are the leading players offering cell therapy packaging services and products? What are the key considerations and challenges associated with cell therapy packaging? Which partnership models are commonly adopted by stakeholders engaged in this industry? Which players are likely to partner with cell therapy packaging service and product providers? What factors are likely to influence the evolution of the cell therapy packaging service providers market? What are the likely future trends in cell therapy packaging services market? How is the current and future opportunity likely to be distributed across key market segments?
RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.
The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views
While the focus has been on forecasting the market till 2030, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.
CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.
Chapter 3 provides a general introduction to the pharmaceutical filling and packaging, including information on types of pharmaceutical packaging. The chapter lays emphasis on cell therapy packaging, primary and secondary packaging of cell therapies. In addition, it discusses the key considerations and challenges associated with cell therapy packaging.
Chapter 4 features an overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis on the year of establishment, company size and location of headquarters. In addition, the chapter highlights the analysis on the package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen) and type of passive system used. Further, the chapter also presents analysis on temperature ranges supported, type of cells handled and additional services offered.
Chapter 5 fpresents a detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players.
Chapter 6 includes profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.
Chapter 7 presents in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies).
Chapter 8 provides an analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership.
Chapter 9 presents a list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate).
Chapter 10 features a case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies.
Chapter 11 presents a detailed market forecast analysis, providing insights on the likely growth of continuous manufacturing equipment providers market for the period 2021-2030. In addition, the chapter presents the likely distribution of the projected future opportunity based on type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), package engineering design (primary and secondary packaging), scale of operation (clinical and commercial) and geography (North America, Europe, Asia Pacific and Rest of the World).
Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of cell therapy products and services market.
Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p06130493/?utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
See more here:
Cell Therapy Packaging Products and Services Market by Type - GlobeNewswire
- Cell Therapy Basics - February 21st, 2024
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022
- Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire - October 13th, 2022
- CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire - October 13th, 2022
- Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors - PR Newswire - October 13th, 2022
- Cell Therapy Technologies Market Expected to Reach US ~$12.27 Billion and CAGR 14.5% by 2030 Polaris Market Research - Digital Journal - October 13th, 2022
- Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies - Precision Oncology News - October 13th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - PR Newswire - October 13th, 2022
- Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases -... - October 13th, 2022
- Breast cancer treatment: These targeted therapies are a ray of hope for patients - Health shots - October 13th, 2022
- Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022 - PR Newswire - October 13th, 2022
- Mayo Clinic Minute: What is CAR-T cell therapy? - Finger Lakes Times - October 13th, 2022
- Gamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon Platform USA - English - USA - English - PR... - October 13th, 2022
- Merck and Moderna Move Forward with Personalized Cancer Vaccine - BioSpace - October 13th, 2022
- First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study - Targeted Oncology - October 13th, 2022
- MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 - Yahoo Finance - October 13th, 2022
- Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire - October 13th, 2022
- Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy -... - October 13th, 2022
- Integrating CAR T-Cell Therapy Into Community Oncology Practices - Targeted Oncology - October 4th, 2022
- About CAR-T cell therapy - Mayo Clinic - October 4th, 2022
- Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by... - October 4th, 2022
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B... - October 4th, 2022
- Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News - October 4th, 2022
- City of Hope To Accelerate Immunotherapy Research And Treatment Innovation with $15 Million Gift From Ted Schwartz Family - City of Hope - October 4th, 2022
- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - Business Wire - October 4th, 2022
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors - Yahoo Finance - October 4th, 2022
- SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy -... - October 4th, 2022